Published in J Control Release on August 21, 2012
Hydrogel-forming microneedles increase in volume during swelling in skin, but skin barrier function recovery is unaffected. J Pharm Sci (2014) 0.82
Diclofenac enables unprecedented week-long microneedle-enhanced delivery of a skin impermeable medication in humans. Pharm Res (2013) 0.80
Development of in vivo impedance spectroscopy techniques for measurement of micropore formation following microneedle insertion. J Pharm Sci (2013) 0.80
Effect of formulation pH on transport of naltrexone species and pore closure in microneedle-enhanced transdermal drug delivery. Mol Pharm (2013) 0.78
The Influence of Solid Microneedles on the Transdermal Delivery of Selected Antiepileptic Drugs. Pharmaceutics (2016) 0.75
Microneedle-assisted percutaneous delivery of naltrexone hydrochloride in yucatan minipig: in vitro-in vivo correlation. Mol Pharm (2013) 0.75
Optimization of naltrexone diclofenac codrugs for sustained drug delivery across microneedle-treated skin. Pharm Res (2013) 0.75
Transdermal drug delivery. Nat Biotechnol (2008) 5.11
Microneedles for transdermal drug delivery. Adv Drug Deliv Rev (2004) 4.37
Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery. Nat Med (2002) 2.42
Lack of pain associated with microfabricated microneedles. Anesth Analg (2001) 2.38
Predicting skin permeability. Pharm Res (1992) 2.16
Transdermal drug delivery: overcoming the skin's barrier function. Pharm Sci Technolo Today (2000) 2.08
Electrical properties of the epidermal stratum corneum. Med Biol Eng (1976) 1.94
Hyaluronic acid: a unique topical vehicle for the localized delivery of drugs to the skin. J Eur Acad Dermatol Venereol (2005) 1.87
Clinical administration of microneedles: skin puncture, pain and sensation. Biomed Microdevices (2009) 1.81
Microneedles permit transdermal delivery of a skin-impermeant medication to humans. Proc Natl Acad Sci U S A (2008) 1.77
Transepidermal water loss: the signal for recovery of barrier structure and function. J Lipid Res (1989) 1.61
Guidelines for measurement of skin colour and erythema. A report from the Standardization Group of the European Society of Contact Dermatitis. Contact Dermatitis (1996) 1.39
Barrier recovery is impeded at neutral pH, independent of ionic effects: implications for extracellular lipid processing. Arch Dermatol Res (1998) 1.34
Relationships between skin's electrical impedance and permeability in the presence of chemical enhancers. J Control Release (2005) 1.25
Parathyroid hormone (1-34)-coated microneedle patch system: clinical pharmacokinetics and pharmacodynamics for treatment of osteoporosis. Pharm Res (2010) 1.21
Kinetics of skin resealing after insertion of microneedles in human subjects. J Control Release (2011) 1.21
Microneedle arrays allow lower microbial penetration than hypodermic needles in vitro. Pharm Res (2009) 1.14
A predictive algorithm for skin permeability: the effects of molecular size and hydrogen bond activity. Pharm Res (1995) 1.09
Evaluation of the skin surface hydration in vivo by electrical measurement. J Invest Dermatol (1980) 1.08
Diclofenac enables prolonged delivery of naltrexone through microneedle-treated skin. Pharm Res (2011) 1.07
Prostaglandin-H-synthase isozyme expression in normal and neoplastic human skin. Int J Cancer (1999) 1.05
Multicentre study for the development of an in vivo model to evaluate the influence of topical formulations on irritation. Contact Dermatitis (2000) 1.00
The electrical characteristics of human skin in vivo. Pharm Res (1995) 0.95
Non-invasive assessment of the effect of formulation excipients on stratum corneum barrier function in vivo. Int J Pharm (2004) 0.93
Physicochemical aspects of percutaneous penetration and its enhancement. Pharm Res (1988) 0.92
In-vivo dynamic characterization of microneedle skin penetration using optical coherence tomography. J Biomed Opt (2010) 0.92
The use of silicon microfabrication technology in painless blood glucose monitoring. Diabetes Technol Ther (2000) 0.92
Recovery of skin barrier properties after sonication in human subjects. Ultrasound Med Biol (2009) 0.91
Regulation of cutaneous drug-metabolizing enzymes and cytoprotective gene expression by topical drugs in human skin in vivo. Br J Dermatol (2006) 0.91
Current aspects of formulation efforts and pore lifetime related to microneedle treatment of skin. Expert Opin Drug Deliv (2010) 0.90
In vivo evaluation of a transdermal codrug of 6-beta-naltrexol linked to hydroxybupropion in hairless guinea pigs. Eur J Pharm Sci (2008) 0.87
Skin surface electric potential as an indicator of skin condition: a new, non-invasive method to evaluate epidermal condition. Exp Dermatol (2008) 0.80
Post-iontophoresis recovery of human skin impedance in vivo. Eur J Pharm Biopharm (2002) 0.79
In vivo ac impedance spectroscopy of human skin. Theory and problems in monitoring of passive percutaneous drug delivery. Ann N Y Acad Sci (1999) 0.78
Patient perspectives on the impact of fibromyalgia. Patient Educ Couns (2008) 2.57
A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum (2004) 2.48
Identifying the clinical domains of fibromyalgia: contributions from clinician and patient Delphi exercises. Arthritis Rheum (2008) 2.22
Momentary relationship between cortisol secretion and symptoms in patients with fibromyalgia. Arthritis Rheum (2005) 1.98
Chronic widespread pain and fibromyalgia: what we know, and what we need to know. Best Pract Res Clin Rheumatol (2003) 1.94
Fibromyalgia syndrome module at OMERACT 9: domain construct. J Rheumatol (2009) 1.87
Microneedles permit transdermal delivery of a skin-impermeant medication to humans. Proc Natl Acad Sci U S A (2008) 1.77
Self-regulatory deficits in fibromyalgia and temporomandibular disorders. Pain (2010) 1.68
Fibromyalgia: where are we a decade after the American College of Rheumatology classification criteria were developed? Arthritis Rheum (2002) 1.58
Linking disease symptoms and subtypes with personalized systems-based phenotypes: a proof of concept study. Brain Behav Immun (2012) 1.53
Fibromyalgia syndrome. J Rheumatol (2005) 1.49
Challenges and opportunities in dermal/transdermal delivery. Ther Deliv (2010) 1.32
High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood (2002) 1.26
Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med (2003) 1.25
Sequential induction of pro- and anti-inflammatory prostaglandins and peroxisome proliferators-activated receptor-gamma during normal wound healing: a time course study. Prostaglandins Leukot Essent Fatty Acids (2007) 1.14
A symptom-based approach to pharmacologic management of fibromyalgia. Nat Rev Rheumatol (2009) 1.13
Biology and therapy of fibromyalgia. Evidence-based biomarkers for fibromyalgia syndrome. Arthritis Res Ther (2008) 1.11
Potential roles of microsomal prostaglandin E synthase-1 in rheumatoid arthritis. Inflamm Regen (2011) 1.11
Sleep stage dynamics in fibromyalgia patients and controls. Sleep Med (2008) 1.10
Transdermal delivery of naltrexol and skin permeability lifetime after microneedle treatment in hairless guinea pigs. J Pharm Sci (2010) 1.09
Toxoplasma gondii inhibits ultraviolet light-induced apoptosis through multiple interactions with the mitochondrion-dependent programmed cell death pathway. Cell Microbiol (2006) 1.08
Diclofenac enables prolonged delivery of naltrexone through microneedle-treated skin. Pharm Res (2011) 1.07
Enhancement of transdermal delivery of 6-beta-naltrexol via a codrug linked to hydroxybupropion. J Control Release (2006) 1.03
Transdermal delivery of naltrexone and its active metabolite 6-beta-naltrexol in human skin in vitro and guinea pigs in vivo. J Pharm Sci (2005) 1.03
Use of NSAIDs in treating patients with arthritis. Arthritis Res Ther (2013) 1.03
Flux across [corrected] microneedle-treated skin is increased by increasing charge of naltrexone and naltrexol in vitro. Pharm Res (2008) 1.01
Programmable transdermal drug delivery of nicotine using carbon nanotube membranes. Proc Natl Acad Sci U S A (2010) 1.01
In vitro permeation of a pegylated naltrexone prodrug across microneedle-treated skin. J Control Release (2010) 1.00
The effect of anxiety and depression on improvements in pain in a randomized, controlled trial of pregabalin for treatment of fibromyalgia. Pain Med (2007) 1.00
Content and criterion validity of the preliminary core dataset for clinical trials in fibromyalgia syndrome. J Rheumatol (2009) 0.99
In vivo evaluation of 3-O-alkyl ester transdermal prodrugs of naltrexone in hairless guinea pigs. J Control Release (2005) 0.98
Human skin permeation of branched-chain 3-0-alkyl ester and carbonate prodrugs of naltrexone. Pharm Res (2005) 0.98
Rheumatoid arthritis and salivary biomarkers of periodontal disease. J Clin Periodontol (2010) 0.98
Transdermal delivery of bupropion and its active metabolite, hydroxybupropion: a prodrug strategy as an alternative approach. J Pharm Sci (2009) 0.96
Chronic opioid use in fibromyalgia syndrome: a clinical review. J Clin Rheumatol (2013) 0.96
Vehicle composition influence on the microneedle-enhanced transdermal flux of naltrexone hydrochloride. Pharm Res (2010) 0.95
Objective measures of disordered sleep in fibromyalgia. J Rheumatol (2009) 0.94
Development of responder definitions for fibromyalgia clinical trials. Arthritis Rheum (2012) 0.93
Defective generation of a humoral immune response is associated with a reduced incidence and severity of collagen-induced arthritis in microsomal prostaglandin E synthase-1 null mice. J Immunol (2008) 0.92
Impaired sleep quality in fibromyalgia: Detection and quantification with ECG-based cardiopulmonary coupling spectrograms. Sleep Med (2009) 0.92
Microsomal prostaglandin E synthase-1: the inducible synthase for prostaglandin E2. Arthritis Res Ther (2005) 0.91
Toward development of a fibromyalgia responder index and disease activity score: OMERACT module update. J Rheumatol (2011) 0.91
Synthesis and hydrolytic behavior of two novel tripartate codrugs of naltrexone and 6beta-naltrexol with hydroxybupropion as potential alcohol abuse and smoking cessation agents. Bioorg Med Chem (2006) 0.91
Prostaglandin E2 differentially modulates proinflammatory/prodestructive effects of TNF-alpha on synovial fibroblasts via specific E prostanoid receptors/cAMP. J Immunol (2009) 0.91
Development and validation of a liquid chromatography-mass spectrometry method for the quantitation of naltrexone and 6beta-naltrexol in guinea pig plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 0.91
A duplex "Gemini" prodrug of naltrexone for transdermal delivery. J Control Release (2004) 0.91
Memory beliefs and function in fibromyalgia patients. J Psychosom Res (2005) 0.90
Microsomal prostaglandin E synthase-1 deficiency is associated with elevated peroxisome proliferator-activated receptor gamma: regulation by prostaglandin E2 via the phosphatidylinositol 3-kinase and Akt pathway. J Biol Chem (2006) 0.90
In vitro/in vivo correlation of transdermal naltrexone prodrugs in hairless guinea pigs. Pharm Res (2005) 0.90
Association of smoking and chronic pain syndromes in Kentucky women. J Pain (2011) 0.90
Current aspects of formulation efforts and pore lifetime related to microneedle treatment of skin. Expert Opin Drug Deliv (2010) 0.90
Bioconversion of naltrexone and its 3-O-alkyl-ester prodrugs in a human skin equivalent. J Pharm Sci (2005) 0.89
Physicochemical evaluation, in vitro human skin diffusion, and concurrent biotransformation of 3-O-alkyl carbonate prodrugs of naltrexone. Pharm Res (2004) 0.89
Epidemiology of Down syndrome: new insight into the multidimensional interactions among genetic and environmental risk factors in the oocyte. Am J Epidemiol (2011) 0.89
The effects of pregabalin on sleep disturbance symptoms among individuals with fibromyalgia syndrome. Sleep Med (2009) 0.88
Near-infrared spectrometry for the quantification of dermal absorption of econazole nitrate and 4-cyanophenol. Pharm Res (2006) 0.88
mPGES-1 null mice are resistant to bleomycin-induced skin fibrosis. Arthritis Res Ther (2011) 0.87
Association of fibromyalgia with altered skeletal muscle characteristics which may contribute to postexertional fatigue in postmenopausal women. Arthritis Rheum (2013) 0.87
In vivo evaluation of a transdermal codrug of 6-beta-naltrexol linked to hydroxybupropion in hairless guinea pigs. Eur J Pharm Sci (2008) 0.87
Implications of glucocorticoid therapy in idiopathic inflammatory myopathies. Nat Rev Rheumatol (2012) 0.87
Pharmacokinetic and pharmacodynamic profile of supratherapeutic oral doses of Δ(9) -THC in cannabis users. J Clin Pharmacol (2013) 0.87
Controversies in COX-2 selective inhibition. J Rheumatol (2002) 0.86
Development of a codrug approach for sustained drug delivery across microneedle-treated skin. J Pharm Sci (2013) 0.86
Prostaglandin E2 activates Rap1 via EP2/EP4 receptors and cAMP-signaling in rheumatoid synovial fibroblasts: involvement of Epac1 and PKA. Prostaglandins Other Lipid Mediat (2009) 0.86
Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine. Arthritis Res Ther (2012) 0.86
The association of adverse pregnancy events and cardiovascular disease in women 50 years of age and older. J Womens Health (Larchmt) (2011) 0.86
Intrauterine group A streptococcal infections are exacerbated by prostaglandin E2. J Immunol (2013) 0.85
Prostaglandin E2 induction during mouse adenovirus type 1 respiratory infection regulates inflammatory mediator generation but does not affect viral pathogenesis. PLoS One (2013) 0.85
Violence against women and postpartum depression. J Womens Health (Larchmt) (2011) 0.84
New insights into the benefits of exercise for muscle health in patients with idiopathic inflammatory myositis. Curr Rheumatol Rep (2014) 0.84
Chromosome 21 non-disjunction and Down syndrome birth in an Indian cohort: analysis of incidence and aetiology from family linkage data. Genet Res (Camb) (2010) 0.84
In vitro experiment optimization for measuring tetrahydrocannabinol skin permeation. Int J Pharm (2002) 0.84
Fluvastatin as a micropore lifetime enhancer for sustained delivery across microneedle-treated skin. J Pharm Sci (2014) 0.83
Unilateral lung hypoplasia: a rare cause of unilateral opaque hemithorax in chest X-ray in a young boy. Indian J Med Sci (2013) 0.83
Somatic cell plasticity and Niemann-Pick type C2 protein: fibroblast activation. J Biol Chem (2010) 0.82
In vitro release studies on matrix type transdermal drug delivery systems of naltrexone and its acetyl prodrug. Drug Dev Ind Pharm (2005) 0.82
Salivary cortisol and cold pain sensitivity in female twins. Ann Behav Med (2014) 0.82
Regulation of B lymphocytes and plasma cells by innate immune mechanisms and stromal cells in rheumatoid arthritis. Expert Rev Clin Immunol (2014) 0.81
In vitro skin diffusion study of pure forskolin versus a forskolin-containing Plectranthus barbatus root extract. J Nat Prod (2009) 0.81
Major enzymatic pathways in dermal wound healing: current understanding and future therapeutic targets. Curr Opin Investig Drugs (2006) 0.81
Gastric antral vascular ectasia and its clinical correlates in patients with early diffuse systemic sclerosis in the SCOT trial. J Rheumatol (2013) 0.81
Human skin permeation of 3-O-alkyl carbamate prodrugs of naltrexone. J Pharm Sci (2009) 0.81
Transdermal delivery of the synthetic cannabinoid WIN 55,212-2: in vitro/in vivo correlation. Pharm Res (2004) 0.81
In vitro/in vivo correlation studies for transdermal delta 8-THC development. J Pharm Sci (2004) 0.81
Noninvasive optical characterization of muscle blood flow, oxygenation, and metabolism in women with fibromyalgia. Arthritis Res Ther (2012) 0.81
Is there a place for non-selective NSAIDs in the treatment of arthritis? Joint Bone Spine (2002) 0.80
Development and testing of the fibromyalgia diagnostic screen for primary care. J Womens Health (Larchmt) (2011) 0.80
Naltrexone salt selection for enhanced transdermal permeation through microneedle-treated skin. J Pharm Sci (2012) 0.80
Diclofenac enables unprecedented week-long microneedle-enhanced delivery of a skin impermeable medication in humans. Pharm Res (2013) 0.80
Determining dermal absorption parameters in vivo from tape strip data. Pharm Res (2002) 0.80
Development of in vivo impedance spectroscopy techniques for measurement of micropore formation following microneedle insertion. J Pharm Sci (2013) 0.80